HCV NS4a Modified NS3 Polypeptides for Stable Immunoassays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools for hepatitis C virus (HCV) infection lack sensitivity and accuracy, particularly in early detection and differentiation among the six known genotypes, leading to challenges in patient care and transmission prevention.
Innovation Solution
Development of NS4a/modified NS3 HCV polypeptides that retain conformational epitopes, inhibiting protease activity to enhance immunoreactivity and stability, allowing for accurate detection of HCV infection using immunoassays, including combination assays with anti-HCV antibodies and antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native NS3 protease domain is used in diagnostic assays, then the polypeptide can be produced and processed naturally, but the protease activity causes self-hydrolysis and cleavage of assay reagents, reducing stability and reliability
Solution Approach 1:
The harmful protease activity is extracted and removed from the NS3 domain by replacing the catalytic triad residues (His, Asp, Ser) with non-catalytic amino acids (Ala, Gly, Val). This eliminates the self-hydrolysis problem while preserving the immunogenic and diagnostic functions of the polypeptide structure.
Solution Approach 2:
The chemical parameters of the NS3 domain are changed by substituting specific amino acid residues at key positions. The catalytic triad (His, Asp, Ser) is replaced with non-catalytic residues, fundamentally changing the biochemical property from active protease to stable structural domain, thereby eliminating harmful autocleavage while maintaining immunoreactivity.
2Measurement precision
If conventional diagnostic tools are used, then the assays can be performed with standard reagents, but the sensitivity and accuracy in early detection and genotype differentiation are insufficient
Solution Approach 1:
The polypeptide is designed with heterogeneous local qualities by combining different HCV domain segments (NS4a, NS3, and linker regions) with distinct functional properties. The NS4a region provides immunogenicity, the modified NS3 provides structural stability, and the linker provides flexibility, creating a composite reagent with superior overall performance for detection sensitivity and genotype differentiation.
Solution Approach 2:
The diagnostic reagent is constructed as a composite polypeptide combining multiple HCV protein domains (NS4a fused to modified NS3) with complementary functions. This composite structure integrates the immunogenic properties of NS4a with the stable scaffold of modified NS3, creating a reagent that outperforms conventional single-domain reagents in sensitivity, accuracy, and reliability across all six HCV genotypes.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Modified hepatitis C virus polypeptides are described. The polypeptides include the HCV NS4a domain and modified NS3 domain. The polypeptides retain conformational epitopes. HCV immunoassays including the polypeptides are also described.